Promotie onderzoek

A prospective observational PK/PD to study the target attainment for β-lactam antibiotics in critically ill pediatric patients and associated risk factors.

The aim of this project is to achieve more effective patient treatments with antibiotics by quantifying the concentrations at the site of infection with minimal sample volumes. To enable quantification of antibiotics at the site of infection, multiple assays should be developed and validated in these infected matrices, such as synovial fluid, synovial tissue, bone, and vitreous humor. Furthermore, the focus will be on small-volume samples and more patient friendly, and sustainable sample preparations.
 

A prospective observational PK/PD to study the target attainment for β-lactam antibiotics in critically ill pediatric patients and associated risk factors.
 

This thesis explores how systemic inflammation and continuous renal replacement therapy (CRRT) influence drug pharmacokinetics in critically ill patients. Key research questions include: How does inflammation alter midazolam metabolism in critically ill COVID-19 patients? What impact does CRRT have on the drug CL and efficacy of commonly administered drugs at the ICU? The findings aim to optimize therapeutic approaches in critically ill patients.
 

Aim is to investigate the occurence and prevention of anti-cancer treatment, particularly immune checkpoint inhibitors. 
 

To determine the need for repeated booster vaccinations in healthy individuals and to aid policymakers in future public health interventions for COVID-19. Gain insight into the immunogenicity of the additional bivalent booster vaccination in a representative sample of the healthy Dutch population. We aim to investigate three main topics: 
i) immunogenicity of bivalent vaccines after priming with adenovirus- or mRNA-based vaccines, 
ii) immunological recall responses and reactivity with relevant variants after booster vaccination, and 
iii) the necessity of booster vaccinations for the healthy population in the future.